Evelyne Yehudit Bischof at ARDD2025: Healthspan Protocol in the Clinical Practice

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the practical application of healthspan protocols, particularly in oncology, cardiology, and geriatrics. The argumentation is based on preliminary data from ongoing studies, which adds a real-world perspective but also limits the strength of conclusions. The speaker effectively argues for the integration of biological age clocks and functional assessments into clinical decision-making, supported by examples such as the TAVI study where biological age predicted outcomes. However, many findings are not statistically significant, and the cohorts are heterogeneous, which weakens the overall argument. The speaker acknowledges these limitations and emphasizes the need for further research.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates a reasonable level of scientific rigor, with references to ongoing studies and collaborations. However, specific sources are not cited in the talk, and the data are preliminary. The title accurately reflects the content, focusing on healthspan protocols in clinical practice. The speaker is a recognized expert in the field, which adds credibility. The lack of detailed methodology and peer-reviewed publications limits the overall reliability.

The title accurately reflects the content: a presentation on integrating healthspan protocols into clinical practice, focusing on various patient populations and biomarkers.

7/10

Presentation of preliminary data from ongoing studies at Sheba Longevity Center, with some methodological limitations (e.g., mixed cohorts, no significance in some analyses). The speaker is a recognized expert, but the content is largely anecdotal and not peer-reviewed at this stage.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and overview of healthy longevity medicine
• 02:00Discussion on populations covered by healthy longevity medicine
• 05:00Introduction to oncology studies and geroncology
• 10:00Presentation of cancer survivor cohort data (SHARP study)
• 15:00Cardiology studies: biological age clocks and TAVI outcomes
• 20:00Andropause study and cognitive health with digital brain training
• 25:00Conclusion and call for collaboration

• ARDD2025 Conference — Conference where the talk was presented

• Epigenetic Clocks — Supports the use of biological age clocks in clinical practice.
• Sarcopenia in Cancer Survivors — Literature supporting the prevalence of sarcopenia in cancer survivors.

• Telomere Length as Biomarker — The speaker found no correlation between telomere length and biological age, conflicting with some studies suggesting telomere length as a biomarker.